Histamine H3 receptor antagonist JNJ-39220675 shows promise against alcoholism Jan. 21, 2011 No Comments
Orexo's new sublingual tablet formulation of buprenorphine/naloxone completes phase I trial Dec. 15, 2010 No Comments
Aoxing Pharma begins trial of sublingual buprenorphine/naloxone for opioid addiction Dec. 13, 2010 No Comments
CBLB-502 receives FDA orphan drug status for prevention of death following irradiation Dec. 1, 2010 No Comments
RSS